17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

      1 , 1 , 2 , 3 , 3 , 3 , 3 , 4 , 4 , 4 , 5 , 5 , 5 , 6 , 6 , 7 , 7 , 8 , 7 , 9 , 10 , 10 , 11 , 12 , 13 , 14 , 15 , 15 , 16 , 17 , 18 , 18 , 19 , 1
      JAMA neurology
      American Medical Association (AMA)

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of genetic Parkinson disease (PD) known to date. The clinical features of manifesting LRRK2 mutation carriers are generally indistinguishable from those of patients with sporadic PD. However, some PD cases associated with LRRK2 mutations lack Lewy bodies (LBs), a neuropathological hallmark of PD. We investigated whether the presence or absence of LBs correlates with different clinical features in LRRK2-related PD.

          Related collections

          Author and article information

          Journal
          JAMA Neurol
          JAMA neurology
          American Medical Association (AMA)
          2168-6157
          2168-6149
          Jan 2015
          : 72
          : 1
          Affiliations
          [1 ] The Edmond J. Safra Program in Parkinson's Disease, University Health Network, Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
          [2 ] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
          [3 ] Mayo Clinic, Jacksonville, Florida.
          [4 ] University of Pennsylvania, Philadelphia.
          [5 ] Columbia University, New York, New York.
          [6 ] Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain.
          [7 ] Hospital Universitario Donostia, CIBERNED, San Sebastián, Spain.
          [8 ] Bellvitge University Hospital, L' Hospitalet de Llobregat, Barcelona, Spain.
          [9 ] Veterans Affairs Medical Center, San Francisco, California.
          [10 ] The Parkinson's Institute, Sunnyvale, California.
          [11 ] St Olavs Hospital, Trondheim, Norway.
          [12 ] University of Turin, Turin, Italy.
          [13 ] Erasmus MC, Rotterdam, the Netherlands.
          [14 ] Skåne University Hospital and Lund University, Lund, Sweden.
          [15 ] Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy.
          [16 ] Centre Hospitalier Universitaire La Timone, Marseille, France.
          [17 ] Sagamihara National Hospital, Kanagawa, Japan.
          [18 ] Sorbonne Université, Pierre and Marie Curie University, Institut du Cerveau et de la Moelle Epinière, Institut National de la Santé et de la Recherche Médicale, Centre national de la recherche scientique, Paris, France.
          [19 ] University of British Columbia, Vancouver, British Columbia, Canada.
          Article
          1934714 NIHMS678094
          10.1001/jamaneurol.2014.2704
          4399368
          25401511
          9b349f4a-0e3c-4274-b18e-54f0dc0863a3
          History

          Comments

          Comment on this article